Metavia Provided an Update on Its Ongoing Collaboration With Syntekabio, Leveraging Deepmatcher Platform, Confirming Strong Inflammatory And Cardiometabolic Target Engagement, Supporting Development in MASH and Potential Type 2 Diabetes

Using AI-based compound-protein interaction modeling, Syntekabio has identified key disease targets for MetaVia's oral G-protein-coupled receptor 119 (GPR119) agonist, vanoglipel (DA-1241). The analysis highlighted inflammatory diseases, cardiometabolic disorders, and cancer as the top predicted target areas, directly aligning with MetaVia's therapeutic focus. Notably, cancer was identified, in part, due to the strong reduction in inflammation observed in AI-predicted target pathways.

"The AI modeling results provide strong confirmation that vanoglipel engages key inflammatory targets, which supports our strategy in metabolic dysfunction-associated steatohepatitis (MASH) and potential type 2 diabetes (T2D)," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "Furthermore, the identification of inflammation, cardiometabolic, and cancer-related pathways reinforces that we are focused in the right therapeutic areas. MetaVia continues to advance DA-1241 for MASH and T2D, bolstered by our Phase 2a clinical study results which demonstrated direct hepatic activity, improvements in glucose metabolism, and a favorable safety and tolerability profile in 109 patients over 16 weeks. Together, these insights give us confidence in DA-1241's broader therapeutic potential."

MetaVia will continue leveraging the Syntekabio AI platform to explore additional indications and further optimize the therapeutic profile of vanoglipel.